Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Keros Therapeutics Inc KROS

Biotechnology
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or... see more

Recent & Breaking News (NDAQ:KROS)

Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer

GlobeNewswire October 16, 2024

Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference

GlobeNewswire September 12, 2024

Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial

GlobeNewswire September 3, 2024

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

GlobeNewswire August 28, 2024

Keros Therapeutics Reports Second Quarter 2024 Financial Results

GlobeNewswire August 7, 2024

Keros Therapeutics Announces Leadership Updates

GlobeNewswire June 17, 2024

Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association

GlobeNewswire June 17, 2024

Keros Therapeutics to Host a Corporate Update Conference Call and Webcast

GlobeNewswire June 4, 2024

Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire June 3, 2024

Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors

GlobeNewswire May 28, 2024

Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association

GlobeNewswire May 14, 2024

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

GlobeNewswire May 8, 2024

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

GlobeNewswire March 14, 2024

Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference

GlobeNewswire March 5, 2024

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire February 28, 2024

Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress

GlobeNewswire January 29, 2024

Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock

GlobeNewswire January 9, 2024

Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

GlobeNewswire January 3, 2024

Keros Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire January 3, 2024

Keros Therapeutics to Develop KER-065 for the Treatment of Obesity

GlobeNewswire January 3, 2024